Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR 221.85
-18.90 (-7.85%)
At close: Aug 17, 2026
Medicamen Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,023 | 1,975 | 1,603 | 1,779 | 1,404 | 1,083 |
Other Revenue | 37.77 | 33.86 | 72.21 | 14.26 | 4.58 | 71.55 |
| 2,061 | 2,009 | 1,675 | 1,793 | 1,409 | 1,154 | |
Revenue Growth | 22.21% | 19.90% | -6.56% | 27.29% | 22.02% | 2.42% |
Cost of Revenue | 1,002 | 1,018 | 864.86 | 941.05 | 734.49 | 542.07 |
Gross Profit | 1,059 | 991.11 | 810.61 | 852.01 | 674.19 | 612.38 |
Selling, General & Admin | 361.69 | 349.45 | 353.42 | 335.17 | 218.24 | 155.56 |
Other Operating Expenses | 469.76 | 414.66 | 268.61 | 293.34 | 215.96 | 220.16 |
Operating Expenses | 903.49 | 836.29 | 692.69 | 699.44 | 497.86 | 433.43 |
Operating Income | 155.98 | 154.82 | 117.92 | 152.57 | 176.32 | 178.96 |
Interest Expense | -31.73 | -34.97 | -31.56 | -43.97 | -29.23 | -14.01 |
Interest & Investment Income | - | - | 5.07 | 7.24 | 7.21 | 1.35 |
Currency Exchange Gain (Loss) | - | - | 7.06 | 13.85 | 14.76 | 14.49 |
Other Non Operating Income (Expenses) | -0 | -0 | 0.28 | 0.33 | 1.29 | 0.08 |
EBT Excluding Unusual Items | 124.25 | 119.84 | 98.78 | 130.02 | 170.35 | 180.87 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.02 |
Gain (Loss) on Sale of Assets | - | - | - | 0 | -0.07 | -0.01 |
Pretax Income | 124.25 | 119.84 | 98.8 | 130.76 | 170.45 | 180.95 |
Income Tax Expense | 23.83 | 21.88 | 33.24 | 35.82 | 23.17 | 31.97 |
Earnings From Continuing Operations | 100.42 | 97.96 | 65.56 | 94.94 | 147.29 | 148.98 |
Minority Interest in Earnings | -4.35 | -1.55 | 5.53 | 14.37 | 1.16 | - |
Net Income | 96.07 | 96.41 | 71.08 | 109.31 | 148.44 | 148.98 |
Net Income to Common | 96.07 | 96.41 | 71.08 | 109.31 | 148.44 | 148.98 |
Net Income Growth | 21.45% | 35.64% | -34.97% | -26.36% | -0.36% | 22.82% |
Shares Outstanding (Basic) | 13 | 14 | 13 | 13 | 13 | 12 |
Shares Outstanding (Diluted) | 13 | 14 | 13 | 13 | 13 | 12 |
Shares Change | 8.24% | 6.67% | 0.44% | 0.07% | 3.56% | - |
EPS (Basic) | 7.45 | 7.11 | 5.59 | 8.63 | 11.73 | 12.19 |
EPS (Diluted) | 7.45 | 7.11 | 5.59 | 8.63 | 11.73 | 12.19 |
EPS Growth | 12.21% | 27.15% | -35.25% | -26.41% | -3.78% | 22.82% |
Free Cash Flow | - | -379.5 | -103.47 | -130.31 | -128.94 | -44.99 |
Free Cash Flow Per Share | - | -27.98 | -8.14 | -10.29 | -10.19 | -3.68 |
Dividend Per Share | - | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 51.40% | 49.34% | 48.38% | 47.52% | 47.86% | 53.04% |
Operating Margin | 7.57% | 7.71% | 7.04% | 8.51% | 12.52% | 15.50% |
Profit Margin | 4.66% | 4.80% | 4.24% | 6.10% | 10.54% | 12.90% |
Free Cash Flow Margin | - | -18.89% | -6.18% | -7.27% | -9.15% | -3.90% |
EBITDA | 228.94 | 227 | 187.02 | 221.76 | 238.89 | 235.68 |
EBITDA Margin | 11.11% | 11.30% | 11.16% | 12.37% | 16.96% | 20.41% |
D&A For EBITDA | 72.96 | 72.19 | 69.1 | 69.19 | 62.56 | 56.72 |
EBIT | 155.98 | 154.82 | 117.92 | 152.57 | 176.32 | 178.96 |
EBIT Margin | 7.57% | 7.71% | 7.04% | 8.51% | 12.52% | 15.50% |
Effective Tax Rate | 19.18% | 18.26% | 33.65% | 27.39% | 13.59% | 17.67% |
Revenue as Reported | 2,061 | 2,009 | 1,688 | 1,816 | 1,433 | 1,172 |
Advertising Expenses | - | - | 11.42 | 14.37 | 6.83 | 4.6 |